125 related articles for article (PubMed ID: 15890570)
21. The prognostic value of nestin expression in newly diagnosed glioblastoma: report from the Radiation Therapy Oncology Group.
Chinnaiyan P; Wang M; Rojiani AM; Tofilon PJ; Chakravarti A; Ang KK; Zhang HZ; Hammond E; Curran W; Mehta MP
Radiat Oncol; 2008 Sep; 3():32. PubMed ID: 18817556
[TBL] [Abstract][Full Text] [Related]
22. The natural history of EGFR and EGFRvIII in glioblastoma patients.
Heimberger AB; Suki D; Yang D; Shi W; Aldape K
J Transl Med; 2005 Oct; 3():38. PubMed ID: 16236164
[TBL] [Abstract][Full Text] [Related]
23. Epidermal growth factor receptor extracellular domain mutations in primary glioblastoma.
Idbaih A; Aimard J; Boisselier B; Marie Y; Paris S; Crinière E; Carvalho Silva R; Laigle-Donadey F; Rousseau A; Mokhtari K; Thillet J; Sanson M; Hoang-Xuan K; Delattre JY
Neuropathol Appl Neurobiol; 2009 Apr; 35(2):208-13. PubMed ID: 19284481
[TBL] [Abstract][Full Text] [Related]
24. Mutant epidermal growth factor receptor (EGFRvIII) contributes to head and neck cancer growth and resistance to EGFR targeting.
Sok JC; Coppelli FM; Thomas SM; Lango MN; Xi S; Hunt JL; Freilino ML; Graner MW; Wikstrand CJ; Bigner DD; Gooding WE; Furnari FB; Grandis JR
Clin Cancer Res; 2006 Sep; 12(17):5064-73. PubMed ID: 16951222
[TBL] [Abstract][Full Text] [Related]
25. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data.
Chakravarti A; Dicker A; Mehta M
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):927-31. PubMed ID: 14967452
[TBL] [Abstract][Full Text] [Related]
26. Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: correlation with EGFR status, tumor grade, and survival.
Mizoguchi M; Betensky RA; Batchelor TT; Bernay DC; Louis DN; Nutt CL
J Neuropathol Exp Neurol; 2006 Dec; 65(12):1181-8. PubMed ID: 17146292
[TBL] [Abstract][Full Text] [Related]
27. Expression of CD 73 (ecto-5'-nucleotidase) in 165 glioblastomas by immunohistochemistry and electronmicroscopic histochemistry.
Ludwig HC; Rausch S; Schallock K; Markakis E
Anticancer Res; 1999; 19(3A):1747-52. PubMed ID: 10470109
[TBL] [Abstract][Full Text] [Related]
28. COX-2 expression in hepatocellular carcinoma is an initiation event; while EGF receptor expression with downstream pathway activation is a prognostic predictor of survival.
Foster J; Black J; LeVea C; Khoury T; Kuvshinoff B; Javle M; Gibbs JF
Ann Surg Oncol; 2007 Feb; 14(2):752-8. PubMed ID: 17146741
[TBL] [Abstract][Full Text] [Related]
29. Distinctive E-cadherin and epidermal growth factor receptor expression in metastatic and nonmetastatic head and neck squamous cell carcinoma: predictive and prognostic correlation.
Muller S; Su L; Tighiouart M; Saba N; Zhang H; Shin DM; Chen Z
Cancer; 2008 Jul; 113(1):97-107. PubMed ID: 18473353
[TBL] [Abstract][Full Text] [Related]
30. Effect of epidermal growth factor receptor expression level on survival in patients with epithelial ovarian cancer.
Psyrri A; Kassar M; Yu Z; Bamias A; Weinberger PM; Markakis S; Kowalski D; Camp RL; Rimm DL; Dimopoulos MA
Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8637-43. PubMed ID: 16361548
[TBL] [Abstract][Full Text] [Related]
31. In situ analysis of mutant EGFRs prevalent in glioblastoma multiforme reveals aberrant dimerization, activation, and differential response to anti-EGFR targeted therapy.
Gajadhar AS; Bogdanovic E; Muñoz DM; Guha A
Mol Cancer Res; 2012 Mar; 10(3):428-40. PubMed ID: 22232519
[TBL] [Abstract][Full Text] [Related]
32. The importance of immunohistochemical expression of EGFr in squamous cell carcinoma of the oral cavity treated with surgery and postoperative radiotherapy.
Smid EJ; Stoter TR; Bloemena E; Lafleur MV; Leemans CR; van der Waal I; Slotman BJ; Langendijk JA
Int J Radiat Oncol Biol Phys; 2006 Aug; 65(5):1323-9. PubMed ID: 16750322
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma.
Pelloski CE; Ballman KV; Furth AF; Zhang L; Lin E; Sulman EP; Bhat K; McDonald JM; Yung WK; Colman H; Woo SY; Heimberger AB; Suki D; Prados MD; Chang SM; Barker FG; Buckner JC; James CD; Aldape K
J Clin Oncol; 2007 Jun; 25(16):2288-94. PubMed ID: 17538175
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
[TBL] [Abstract][Full Text] [Related]
35. Membranous expression and prognostic implications of epidermal growth factor receptor protein in human renal cell cancer.
Merseburger AS; Hennenlotter J; Simon P; Kruck S; Koch E; Horstmann M; Kuehs U; Küfer R; Stenzl A; Kuczyk MA
Anticancer Res; 2005; 25(3B):1901-7. PubMed ID: 16158924
[TBL] [Abstract][Full Text] [Related]
36. Epidermal growth factor receptor in undifferentiated carcinoma of the nasopharynx.
Leong JL; Loh KS; Putti TC; Goh BC; Tan LK
Laryngoscope; 2004 Jan; 114(1):153-7. PubMed ID: 14710013
[TBL] [Abstract][Full Text] [Related]
37. Antitumor activity of F90, an epidermal growth factor receptor tyrosine kinase inhibitor, on glioblastoma cell line SHG-44.
Liu FJ; Gui SB; Li CZ; Sun ZL; Zhang YZ
Chin Med J (Engl); 2008 Sep; 121(17):1702-6. PubMed ID: 19024103
[TBL] [Abstract][Full Text] [Related]
38. PI3K-AKT pathway negatively controls EGFR-dependent DNA-binding activity of Stat3 in glioblastoma multiforme cells.
Ghosh MK; Sharma P; Harbor PC; Rahaman SO; Haque SJ
Oncogene; 2005 Nov; 24(49):7290-300. PubMed ID: 16007122
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Metellus P; Coulibaly B; Nanni I; Fina F; Eudes N; Giorgi R; Barrie M; Chinot O; Fuentes S; Dufour H; Ouafik L; Figarella-Branger D
Cancer; 2009 Oct; 115(20):4783-94. PubMed ID: 19637364
[TBL] [Abstract][Full Text] [Related]
40. Lower level of MAPK expression is associated with anthracycline resistance and decreased survival in patients with hormone receptor negative breast cancer.
Derin D; Eralp Y; Ozluk Y; Yavuz E; Guney N; Saip P; Igci A; Ozmen V; Kücücük S; Aslay I; Aydiner A; Topuz E
Cancer Invest; 2008 Aug; 26(7):671-9. PubMed ID: 18608215
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
